Read More Pharma Industry News REGENXBIO monetizes gene therapy royalties in $250m deal with HCRx REGENXBIO advances strategic funding deal with Healthcare Royalty to monetize Zolgensma and pipeline royalties while preserving upside from NAV platform assets and AbbVie/Nippon Shinyaku partnerships. byPallavi MadhirajuMay 20, 2025